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Several studies have shown that high concentrations of
luteinizing hormone (LH) in the follicular phase of stimula-
tion can have a negative effect on oocyte quality, pregnancy
rate and incidence of miscarriage. The aim of the present
study was to examine the effects of highly purified follicle
stimulating hormone (FSH HP) on ovarian stimulation
and particularly on nuclear maturity and morphological
appearance of the oocyte in intracytoplasmic sperm injec-
tion (ICSI) therapy and to compare the results with human
menopausal gonadotrophin (HMG) stimulation. For this
purpose, 50 patients for ICSI (HMG: 30; FSH HP: 20)
and 26 patients for in-vitro fertilization (TVF; HMG: 14,
FSH HP: 12) were stimulated with either HMG OF FSH
HP using a short-term protocol. Patients were divided into
the two groups according to the first letter of their family
name. No differences were observed among the groups in
relation to patient age, duration of stimulation, number
of aspirated oocytes or maturity of the oocyte-cumulus
complex. After removal of the cumulus-corona cells in the
ICSI oocytes, a significantly higher proportion of oocytes
in the FSH HP group were nuclear mature (metaphase II)
than in the HMG group (FSH HP: 88.8%, HMG: 80.6%;
P = 0.009). Furthermore, in the FSH HP group, significantly
fewer oocytes with dark cytoplasm were observed (FSH
HP: 14.4%, HMG: 22.4%; P = 0.02). Fertilization, cleavage
and pregnancy rates (FSH HP 38%, HMG: 34% per
retrieval) were comparable in both groups. Based on the
results obtained, it can be concluded that the short-term
FSH HP treatment protocol synchronizes oocyte maturation
better than comparable stimulation with HMG.
Key words: follicle stimulating hormone/human menopausal
gonadotrophin/intracytoplasmic sperm injection/nuclear maturity
Introduction
The most commonly used agent worldwide for ovarian stimula-
tion is human menopausal gonadotrophin (HMG), which is a
1 • 1 mixture of follicle stimulating hormone (FSH) and lutein-
izing hormone (LH). Several studies suggest that high concen-
trations of LH during the follicular phase of stimulation can
have a negative impact on oocyte quality, pregnancy rate and
incidence of miscarriage (Stanger and Yovich, 1985; Howies
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et al, 1986; Homburg et al., 1988; Regan et al., 1990; Shoham
et al, 1990). Several centres therefore substituted HMG
partially or completely by pure FSH (Venturoli et al, 1986;
Diedrich et al., 1987). In spite of die misgivings about LH,
no comparative in-vitro fertilization (TVF) study has to date
been able to demonstrate the superiority of pure FSH over
HMG (Bentick et al, 1988; Edelstein et al., 1990; Tanbo
et al, 1990; Check et al, 1995), with the exception of a
controversial meta-analysis (Daya, 1995).
It is possible that no differences were found because,
although HMG and FSH may indeed be different, die difference
is in fact clinically irrelevant It could, however, also be due
to the fact that the sensitivity, specificity and precision of
measurement of the parameters studied were too weak. In the
studies cited, oocyte maturity was assessed indirectly using
the criteria of Veeck (1988), that is, without prior removal of
the cumulus oophorus. Thus, the nuclear maturity and the
morphological appearance of die oocytes themselves could not
be examined.
In contrast to conventional TVF, oocytes are routinely
separated from die cumulus oophorus in microinsemination
techniques (Imthurn et al, 1995). As the morphological
structure of the denuded oocytes can be assessed in a more
detailed and precise manner, this procedure permits a more
clearly denned differentiation of diese cells.
Both the degree of maturity and the morphology of die
oocytes are significantly more directly dependent on the
stimulation used dian, for example, fertilization. Hence, diese
parameters are better markers than the fertilization rate to
score the quality of the stimulation. The magnitude of the
fertilization rate not only correlates with oocyte quality, but
also, among other factors, with die quality of the spermatozoa,
the culture conditions and, particularly in the case of micro-
insemination, with technique and experience. At present, no
studies are available that have investigated the nuclear maturity
and morphology of denuded oocytes and compared the results
widi respect to the stimulation used.
The aim of the present study was to examine the effects of
FSH HP on ovarian stimulation and particularly on nuclear
maturity and oocyte morphology in intracytoplasmic sperm
injection (ICSI) therapy and to compare the results with those
obtained when HMG is used.
Materials and methods
The study was examined and approved by the local ethical committee.
A total of 93 ICSI and IVF cycles were stimulated with either HMG
or FSH HP using a short-term protocol Patients were divided into
the two groups one after the other according to the first letter of their
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family name (A-L: HMG, M-Z: FSH HP). Patients who presented
for a second treatment during the duration of the study were then
treated with the relevant alternative preparation, so that it could be
conducted in 10 cases as a cross-over. The primary indication for
FVF was always a mechanical factor, and for ICSI severe male
subfertility, except for one case of unexplained infertility. For IVF,
the spermiogram was normal (World Health Organization, 1993).
A total of 53 patients in 53 cycles were stimulated with HMG,
and 40 patients in 40 cycles with FSH HP. For conventional IVF, 37
ovarian stimulations were performed, and 56 stimulations for ICSI.
The average age of the HMG group was not significantly different
from that of the FSH HP group (HMG: 33.1 ± 0.7 years, FSH HP:
34.0 ± 0.6 years; /-test). In addition, no significant difference was
observed in the age of the ICSI subgroups (HMG: 33.2 ± 0.8 years,
FSH HP: 34.0 ± 0.7 years)
Ovarian stimulation has already been described in detail elsewhere
(Imthurn et al., 1992). Briefly summarized, norethisterone acetate
(Primolut-Nor®; Schering, Zurich, Switzerland), at a dose of 10 mg
daily for a duration of 10-25 days, was prescribed to programme the
stimulation. The start of stimulation always commenced with daily
injections of 0.1 mg s.c. D-triptorehne (Decapeptyl®; Ferring,
Duebendorf, Switzerland). Treatment with HMG (Pergonal®, Serono,
Aubonne, Switzerland) or FSH HP (Metrodin HP®; Serono) began
concomitantly (day 1) with the administration of gonadotrophin-
releasing hormone agonist, or 1 or 2 days later (day 2 or 3).
Individualization of the dose was carried Out according to the expected
stimulation response. HMG was injected i.m. by a medically trained
person in the University Hospital of Zurich, or in the patient's home
city. FSH HP was usually injected s.c. by the patient herself. The
dose of the hormone was adapted on stimulation day 6 accofding to
the serum oestradiol concentrations (radioimmunoassay; BioM6rieux,
Marcy l'Etoile, France). Starting on day 8, and then if necessary
daily, vaginal sonography and further oestradiol assays were carried
out. Serum progesterone concentrations (radioimmunoassay;
Amersham, Zurich, Switzerland) were assessed on day 6 and on the
day of ovulation induction. Induction of ovulation was achieved by
the administration of 10 000 IU human chorionic gonadotrophin
(HCG) i.m., if at least two follicles had attained a diameter of 18
mm and the serum oestradiol concentration reached at least 3 nmol/
1 If one or both of these criteria could not be met, the stimulation
was discontinued. The triptoreline injections were stopped at the time
of the HCG administration. Transvaginal follicular aspiration was
earned out 34—36 h later. Aspiration cycles with <3 oocytes were
excluded from the study analysis, as a representative assessment of
an adequate number of oocytes was not possible in these cases.
Immediately after the oocyte retrieval, the oocyte-cumulus complex
(OCC) was assessed by the reproductive biologist using inversion
microscopy (Diaphot TMD; Nikon, Kuesnacht, Switzerland) in
accordance with the criteria of Veeck (1988), and categorized as
being mature, immature or atreac stage. The biologist performing the
assessment was not informed which stimulation had been used for
which patients. In the case of ICSI, nuclear maturity was assessed
after removal of the cumulus oophorus with hyaluronidase. Oocytes
were judged to be nuclear mature only if a polar body could be
observed in the perivitelline space (metaphase IT). In addition, the
clarity of the cytoplasm and the granularity of the intracellular
granulations were rated for the denuded ICSI oocytes, and cytoplasmic
anomalies such as vacuoles or fragments were looked for.
The insemination and microinsemination techniques and me culture
conditions have also been previously described in detail (Macas etaL,
1990; Imthurn et aL, 1995). Further examination of the oocytes was
carried out 16-18 h after insemination or ICSI, in order to check
fertilization and to record the number of pronuclei. Surplus diploid
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L Comparison of various clinical parameters during stimulation with
human menopausal gonadotrophin (HMG) or highly purified follicle
stimulating hormone (FSH HP)
HMG FSH HP
Duration of stimulation (days)
ICSI (n = 56)
IVF (n = 37)
dumber of ampoules (75 IU)
ICSI (n = 56)
IVF (n = 37)
Oestradiol concentration day 6 (nmol/1)
ICSI (n = 56)
IVF (n = 37)
Preovulalory oestradiol concentration (nmol/1)
ICSI (n = 56)
IVF (n = 37)
Progesterone concentration day 6 (nmol/1)
ICSI (n = 56)
IVF (n = 37)
Preovulatory progesterone concentration (nmol/1)
ICSI (n = 56)
IVF (n = 37)
Cancelled cycles (n = 93)
No of oocyte retrievals for ICSI*
No. of oocyte retrievals for IVF1
l i o n
11 1 d
10 9 d
312 d
302 d
33.4 d
2.1 d
2 1 d
20 d
12 6 :
12 7 :
12.6:
1.9 :
1.8 :
21 :
45 :
47 :
4.0 :
8%
30
14
; 0.2
t 0.3
t 03
t 20
t 2.4
t 39
t 02
t 0.3
t 04
t 08
t 1 1
t 14
t 01
t 02
t 0.3
t 0.3
t 0.3
t 03
11.0 d
11.2 d
10.8 d
32.5 d
33.4 d
30.9 d
1.7 d
1.7 d
1.9 d
10 6 d
10 5 d
10 8 d
1.8 d
18 :
18 :
4 1 :
42 d
38 d
10%
20
12
: 0.2
: 0.2
t 03
t 18
t 2.2
t 3.1
t 03
t 0.4
t 03
I 08
t 1 1
t 10
t 0.2
t 0.2
t 03
t 02
t 03
t 03
•Cycles with >2 oocytes aspirated.
IVF = ln-vitro fertilization, ICSI = lntracytoplasmic sperm lnjectioa
pronuclear stage zygotes were cryopreserved at this time. A further
24 h later, usually three, and exceptionally four, embryos were
transferred to the cavum uteri. Immediately before the transfer, the
number of blastomeres was recorded and the morphological quality
of the embryos scored (Plachot and Mandelbaum, 1990). The regular-
ity of the blastomeres, clarity of the cytoplasm and presence of
intracellular vacuoles and fragments in the perivitelline space were
noted.
The luteal phase was routinely supported with micronized progester-
one starting from the day of aspiration (vaginal suppositories 100 mg
3X2 daily; Utrogestan®, Golaz, Ecublens, Switzerland).
The results are presented as mean values ± SEM, and were
analysed statistically using Student's i-test (unpaired) and the x2-test
Results were considered significant when P values were <0.05.
Unless a P value is given in the Results, differences between
stimulation protocols or between methods of insemination were not
significantly different
Results
Four stimulations in each of the HMG and the FSH HP groups
had to be discontinued due to poor ovarian response (HMG:
8%, FSH HP: 10%; Table I). A further five HMG and four
FSH HP cycles were not analysed, as in each case the yield
was only one or two oocytes. Thus, 44 HMG and 32 FSH HP
cycles in 50 ICSI (HMG: 30, FSH HP: 20) and 26 IVF (HMG:
14, FSH HP: 12) treatments were included in the study.
The number of ampoules required for HMG and FSH HP
stimulation (HMG: 31.2 ± 2.0, FSH HP: 32.5 ± 1.8 ampoules),
as well as the duration of stimulation (HMG: 11.0 ± 0.2, FSH
HP 11.0 ± 0.2 days) were almost identical in both groups.
There were also no differences within the ICSI group. The
oestradiol and progesterone concentrations on day 6 of the
stimulation and before HCG administration are presented in
Table I. No significant differences were observed either in the
Oocyte quality after stimulation with FSH versus HMG
Table H Matunty and morphological quality of the oocyte-cumulus complexes and of the denuded oocytes after stimulauon with human menopausal
gonadotrophin (HMG) or highly punned follicle stimulating hormone (FSH HP)
HMG FSH HP
Number of oocytes
ICSI (n = 50)
IVF(n = 26)
Oocyte-cumulus complex (mature)
ICSI (n = 613)
IVF (n = 285)
Oocytes in metaphase II (n = 613)
Dark cytoplasm (n = 613)
Coarse-grained granulations (n = 613)
Cytoplasmic anomalies (n = 613)
12 9 ±
133 ±
12 1 ±
92 0%
91.2%
94.1%
80.6%
22 4%
17 3%
8 3%
10
12
1.9
10 3 ± 0.7
10 8 ± 0.9
96 ± 1.3
92.7%
93.5%
91 3%
88 8%
14 4%
18 1%
8.4%
P
P
= 0009
= 002
IVF = in-vitro fertilization, ICSI = intracytoplasmic sperm injection
total sample or in the ICSI subgroup. Although higher mean
preovulatory oestradiol values were measured in the HMG
group, the difference was not statistically significant [HMG:
12.6 ± 0.8 nmol/1 (range 2.2-27.0), FSH HP: 10.6 ±
0.8 nmol/1 (range 4.2-22.0].
A total of 568 and 330 oocytes were aspirated in the HMG
and FSH HP groups respectively (Table H). No statistically
significant difference between the HMG and the FSH HP
group was observed in relation to the average number of
aspirated oocytes [HMG: 12.9 ± 1.0 (range 3-28), FSH HP:
10.3 ± 0.7 oocytes (4-20)]. The proportion of mature OCC
in the HMG group was 92.0%, and 92.7% in the FSH HP
group. When analysed according to the method of insemination,
93.0% of the OCC with IVF (HMG: 94.1%, FSH HP: 91.3%),
and 92.0% of the OCC with ICSI (HMG: 91.2%, FSH HP:
93.5%) were judged to be mature.
After removal of the cumulus oophorus, a polar body in the
perivitelline space could be observed in 83.5% (HMG: 321,
80.6%; FSH HP: 191, 88.8%) of a total of 613 ICSI oocytes
(HMG: 398, 13.3 ± 1.2; FSH HP: 215, 10.8 ± 0.9). This
means that 91 % of the OCC judged to be mature also exhibited
nuclear maturity. In 17.6% of the ICSI oocytes (HMG: 17.3%,
FSH HP: 18.1%), coarse-grained intracellular granulations
were discernible, 19.6% exhibited a dark cytoplasm (Figure 1;
HMG: 22.4%; FSH HP: 14.4%; P = 0.02) and 8.3% showed
cytoplasmic anomalies (HMG: 8.3%; FSH HP: 8.4%). On
average, 9% of the oocytes with ICSI were damaged (HMG:
9.1%; FSH HP: 8.3%).
The fertilization rate with IVF was 69.5% (HMG: 67.1%;
FSH HP: 73.0%) and with ICSI 71.2% (HMG: 69.2%; FSH HP.
74.6%; Table IH). Pronuclear stage zygotes were cryopreserved
after HMG stimulation in 41% (5.7 ± 0.7 pronuclear stages)
and after FSH HP (4.4 ± 0.6 pronuclear stages) in 28% of
the respective cycles. Of the remaining zygotes, 94.2% (HMG:
99.0%; FSH HP: 93.9%) cleaved into predominantly 4-cell
embryos (HMG: 79.6%; FSH HP: 74.3%). A difference in the
rate of cleavage between the two groups was not observed.
This means that the incidence of embryos with less than,
or with more than, four blastomeres was comparable (<4
blastomeres: HMG: 15.5%; FSH HP: 22.8%; >4 blastomeres-
HMG: 4.9%; FSH HP: 2.9%). The incidence of morphologic-
ally regular embryos was practically the same in both groups
(HMG: 74.6%; FSH HP: 76.1%). No transfer was carried out
Figure 1. Denuded oocyte displaying dark cytoplasm (arrow).
Original magnification. X400.
Table IE. Fertilization, cleavage and pregnancy rates after stimulauon with
human menopausal gonadotrophin (HMG) or highly purified follicle
stimulating hormone (FSH HP)
HMG FSH HP
Damaged oocytes after ICSI (n = 512)
Ferulizauon
ICSI (n = 467)
(n = 50)
IVF (n = 285)
(n = 26)
Cleavage rate (n = 330*)
Morphologically regular embryos (n = 311)
Implantauon rate per transferred embryo
Pregnancy rate per retnevalb (n •= 76)
Delivery rate per retrieval (n = 76)
9 1% 8.3%
69 2%
6.7 ± 0 7
67 1%
8 1 it 1.3
99 0%
74 6%
15 6%
34%
23%
74.6%
66 ± 07
73.0%
70 ± 1 1
93.9%
76 1%
16.0%
38%
22%
'After cryopreservauon of 143 pronuclear stage oocytes
includes preclinical pregnancies
IVF = in-vitro ferulizauon, ICSI = lntracytoplasmic sperm injection
2389
B.Imthurn et aL
in three cases in the HMG group, twice because no fertilization
was achieved, and once because all pronuclear stage zygotes
were cryopreserved due to a high risk of severe ovarian
hyperstimulation syndrome. There was one case of no transfer
in the FSH HP group due to lack of fertilization.
A total of 10 patients were stimulated once with HMG and
once with FSH HP. In seven cases, a total of 14ICSI treatments
were carried out. Stimulation in the first cycle was undertaken
with FSH HP on three occasions, and with HMG on four
occasions. Even with this crossed study design, a significant
difference could be observed in the metaphase II oocytes
between HMG and FSH HP stimulation. On average, 10.9 ±
1.2 oocytes (HMG: 11.0 ± 1.7; FSH HP: 10.7 ± 1.9) were
aspirated. After removal of the cumulus oophorus, a polar
body in the perivitelline space was discerned in 88.3% of the
HMG stimulation cases, and in 97.3% of the FSH HP stimula-
tion cases (P = 0.03). No significant difference could be
observed in any of the other parameters studied.
Per transfer, 2.6 ± 0 . 1 (0-4) embryos were replaced. A
pregnancy rate of 34% per retrieval, including prechnical
pregnancies, was obtained in the HMG group. Five patients
aborted (33%), so that a birth rate of 23% was achieved.
Twelve pregnancies were diagnosed in the FSH HP group
(38% per retrieval). Again, five patients aborted, resulting in
a delivery rate of 22%. Three of these pregnancies were twins.
Multiple pregnancies greater than twins did not occur.
Discussion
Comparative investigations in IVF stimulation with HMG and
'pure' FSH have to date not been able to show any superiority
for one or the other stimulation method (Bentick et al, 1988;
Edelstein et al, 1990; Tanbo et al, 1990). These studies used
sample sizes of only 14 to a maximum of 20 cycles per group,
which were clearly too small to test non-specific end-points
such as duration of stimulation, preovulatory oestradiol concen-
trations or pregnancy rates. However, even with greater group
sizes, it is almost impossible to find statistically significant
differences using these markers (Out et al, 1996).
Our results confirm the previously published findings with
'pure' FSH and recombinant FSH (rFSH) in comparison with
HMG (Bentick et al, 1988; Edelstein et al, 1990; Tanbo
et al, 1990; Check et al, 1995; Out et al, 1996), as we
also found no differences in non-specific parameters such as
oestradiol concentrations, number of aspirated oocytes, or
fertilization and pregnancy rates, either in the ICSI sample
studied, or in the IVF group. The present investigation,
however, revealed significant differences between HMG and
FSH HP in specific end-points that have never been examined
in any previous study.
The aim of every stimulation is to yield as many mature
and as few immature oocytes as possible; that is, to attain the
best possible synchronization of follicular maturation. We have
investigated nuclear maturity for the first time as one of the
new specific indicators, and have found a significantly higher
proportion of metaphase II oocytes with FSH HP stimulation
than with the HMG protocol. This observation was confirmed
by the 14 crossed ICSI cycles. In spite of the small sample
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size, the proportion of nuclear mature oocytes after FSH HP
was also found to be higher than after HMG stimulation.
With HMG stimulation, the number of mature oocytes
aspirated was not reduced, but the number of immature oocytes
and consequently the total number of oocytes were increased.
The greater the number of oocytes that develop, the higher
is the oestradiol concentration. The preovulatory oestradiol
concentrations did, indeed, show a tendency to be higher after
HMG stimulation (P = 0.09) than after FSH HP. This is an
unwanted effect, as the risk of ovarian hyperstimulation
syndrome correlates with the magnitude of serum oestradiol
concentrations, and thus increases with raised oestradiol con-
centrations (Schenker and Weinstein, 1978).
When the results of the OCC assessment are considered, it
is striking that no significant difference between the two
stimulation methods was observed for this parameter, which
is also a measure of oocyte maturity; indeed, the results were
practically identical. The reason why significant differences
could be observed for nuclear maturity, but not, however, for
the assessment of the maturity of the OCC, is probably related
to the fact that assessment of maturity based solely on the
extent, clarity and colour of the cumulus cells and the corona
radiata can be misleading. This is because the expansion of
the cumulus cells can be influenced by various factors and
does not necessarily have to correspond to the nuclear maturity
of the oocyte (Elder and Avery, 1992).
No differences between the stimulation protocols could be
found for the assessment of oocyte morphology in relation to
cytoplasmic anomalies and granulations. This, however, was
not the case concerning the clarity of the cytoplasm. Dark
cytoplasm, which was observed significantly less often after
FSH HP stimulation, is interpreted as a sign of incipient
atresia (Veeck, 1988) or, according to our own experience, of
cytoplasmic immaturity. If, in addition to the decreased number
of cytoplasmic dysmature eggs, the higher proportion of
nuclear mature oocytes is also taken into account, it may be
concluded that FSH HP stimulation synchronized follicular
maturation better than HMG stimulation. The extent to which
the morphology of the oocyte really does influence the results
of ICSI, however, is controversial. Thus, De Sutter et al.
(1996) did not find any relationship between the cytoplasmic
appearance of an oocyte and the ICSI fertilization rate. Alikani
et al. (1995), however, reported a higher rate of miscarriage
in women with dysmorphic oocytes.
In our study, we investigated new indicators for the assess-
ment of the quality of stimulation. We also used a different
hormone preparation. FSH HP differs from 'pure' FSH not
only in a further reduction of the proportion of LH present,
but above all in a massive reduction in the content of foreign
protein, whose effect on ovarian stimulation has not been
defined and therefore whose presence is undesired. The present
study, however, cannot answer the question as to which
component is responsible for the better results in comparison
to HMG stimulation. If a low LH and foreign protein content
is considered as being favourable, the development of rFSH
represents even greater progress (Howies et al, 1994; Out
et al, 1995), as rFSH contains absolutely no LH and no
protein with an undefined effect.
Oocyte quality after stimulation with FSH versus HMG
A second limitation of our study was that, although the
biologist who assessed morphology and nuclear maturity of
the oocyte was unaware which stimulation regimen had been
used, the clinician taking the decision about the timing of
administration of HCG was not blinded. However, the
criteria for HCG administration were the same for both the
HMG and the FSH HP regimen. That these criteria were
followed equally in the two groups is shown by the fact that
the duration of stimulation was exactly the same for both
regimens: 11.0 ± 0.2 days. Of course, this does not exclude
an unconscious observer bias, but makes it highly improbable.
In summary, it can be concluded that the FSH HP short-term
stimulation protocol synchronizes oocyte maturation better than
a comparable stimulation with HMG. The proportion of nuclear
mature oocytes is higher, and the number of cytoplasmic
dysmature oocytes lower. The present study, however, did not
elucidate the question as to whether the difference is caused
by the lower LH content, or by the reduction in the amount
of undefined protein.
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